Improved prevention and treatment strategies for differentiation syndrome contribute to reducing early mortality in patients with acute promyelocytic leukemia

Abstract excerpt

With the introduction of differentiating agents, such as all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), the outcomes of patients with acute promyelocytic leukemia (APL) have significantly improved [ 1 , 2 ]. However, there are still many early deaths, especially among those at high risk [ 3 , 4 ]. In our retrospective study of 570 patients with APL, early mortality was 7.54% [ 5 ]. We observed...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Antioxidant Activity and Oxidative Stress
• Share to Retinoids in leukemia and cellular processes